How Tianjin Da Ren Tang’s Revenue Fell 35% While Its Profits Soared: 4 Surprising Insights From Their Financial Report

Introduction: The Profit Paradox

At first glance, the numbers don’t add up. How can a company’s revenue plummet by more than a third while its profits skyrocket by over 170% in the same period? It’s a paradox that would make most investors either scratch their heads in confusion or run for the exits.

But financial statements tell a story, and often the most interesting tales are hidden beneath the headline figures. In this case, a look “under the hood” of Tianjin Pharmaceutical Da Ren Tang Group’s third-quarter report reveals not a business in crisis, but a company executing a deliberate and calculated strategic pivot. Here are four surprising insights that explain how shrinking the top line can lead to a much healthier bottom line.

1. First, They Shrank the Business to Boost Profitability

The most jarring numbers appear right at the top of the income statement. For the first nine months of 2025, the Group’s revenue fell by approximately 35%, dropping from RMB 5,611 million in 2024 to RMB 3,670 million. A drop of that magnitude is typically a massive red flag.

However, the story changes completely when you look at the quality of that revenue. Over the same period, the company’s gross profit margin increased dramatically, from 48% to an impressive 73%.

The explanation for this lies in a structural change to the company. The report states that the primary reason for both the revenue drop and the margin expansion was a “change in the Company’s consolidation scope,” which excluded the data of a lower-margin business, Tianjin Zhongxin Medicine Co., Ltd. (TJZX Medicine).

This wasn’t a sign of operational failure; rather, the numbers reflect a structural change. By removing a high-volume, lower-margin business from its consolidated financials, the Group’s remaining core operations appear far healthier and more profitable. In an industry facing surging raw material costs and pressure on pricing, shedding a lower-margin business is a classic defensive maneuver to protect overall profitability. This move demonstrates a clear choice to prioritize margin quality over revenue quantity.

2. The Profit Spike Came from a Billion-RMB Asset Sale, Not Operations

While improved margins are great, they don’t explain the most dramatic number in the report: a 171% increase in total comprehensive income, which soared to approximately RMB 2,145 million for the first nine months of 2025.

This stunning profit was not driven by a sudden surge in the company’s core business of selling medicine. Instead, the report reveals that the primary source was a one-time gain of approximately RMB 1,542.93 million from the disposal of its equity interest in an associate, Sino-American Tianjin SmithKline & French Lab., Ltd.

This is a crucial distinction for anyone analyzing the company’s performance. By converting a long-held equity investment into over RMB 1.5 billion in cash, the company armed itself with significant capital, providing a strategic war chest in a “reshaping” industry. This was a deliberate decision to transform a passive investment into active capital, signaling a readiness to fund future strategic priorities.

3. Record Profits Didn’t Mean More Cash in the Bank

Here is another counter-intuitive fact from the report: despite booking over RMB 2.1 billion in profit, the Group’s cash and cash equivalents decreased by a staggering 64%, or approximately RMB 1,896 million, since the end of 2024.

So, where did all the money go? The report details two major outflows that account for this decrease:

1. A massive dividend payment: The company paid out approximately RMB 981 million in dividends directly to its shareholders.
2. Large purchases of financial products: The company reallocated a significant portion of its cash into secure investments, with the report specifically highlighting the purchase of approximately RMB 2.57 billion worth of large-denomination certificates of deposit and similar products.

This allocation signals a management team that believes returning capital to owners and preserving it in low-risk assets offers a better return than aggressively reinvesting in its own operational expansion in the current market.

4. This Wasn’t Panic, It Was a Pivot to “Quality and Value First”

Tying all these pieces together is the larger industry context. According to the report, the Traditional Chinese Medicine (TCM) industry is in a “key reshaping phase,” facing “short-term pressure” from challenges like health-insurance cost controls and surging raw material prices.

The company’s actions—structurally improving its margins, cashing out of a major investment, rewarding shareholders, and parking cash—are a direct and strategic response to this tougher environment. These moves are not signs of a company in distress but of one proactively adapting to market realities.

The report uses a specific phrase to describe this new industry focus: a shift from “getting bigger” to “quality and value first.” The company’s seemingly dramatic financial shifts are part of a calculated strategy to fortify its balance sheet and sharpen its focus, positioning it to outlast competitors in a more demanding market.

Conclusion: A New Definition of Winning?

A surface-level glance at a 35% revenue drop would suggest a company in decline. But the real story hidden in the financial details is one of strategic transformation. By choosing profitability over size and security over aggressive expansion, the company has reshaped itself for a new industry reality.

It leaves us with a thought-provoking question for the modern business world, which is often obsessed with endless growth. In an uncertain economic climate, could this company’s calculated decision to shrink be the smartest definition of winning?

WATCH THE EXPLAINER VIDEO BELOW:

LISTEN TO THE PODCAST BELOW:

Related stories: iX Biopharma’s Robust FY2025 Performance and Strategic Outlook